Vaccination After SARS-CoV-2 Infection Increased Antibody Avidity Against the Omicron Variant Compared to Vaccination Alone
- PMID: 35714328
- PMCID: PMC9214134
- DOI: 10.1093/infdis/jiac247
Vaccination After SARS-CoV-2 Infection Increased Antibody Avidity Against the Omicron Variant Compared to Vaccination Alone
Abstract
The SARS-CoV-2 Omicron variant has caused infections among individuals vaccinated or with prior COVID-19, suggesting immune escape. Here, we showed a decrease in binding and surrogate neutralizing antibody responses to the Omicron variant after 2 doses of the Pfizer COVID-19 mRNA vaccine. Individuals recovered from infection before vaccination had higher antibody levels and avidity to the Omicron variant compared to individuals vaccinated without infection. This suggested that COVID-19 infection before vaccination elicited a higher magnitude and affinity antibody response to the Omicron variant, and repeated exposure through infection or vaccine may be required to improve immunity to emerging SARS-CoV-2 variants.
Keywords: COVID-19; SARS-CoV-2; antibody response; vaccine.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Similar articles
-
Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.J Immunol Res. 2022 Aug 31;2022:4813199. doi: 10.1155/2022/4813199. eCollection 2022. J Immunol Res. 2022. PMID: 36093434 Free PMC article.
-
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25. Microbiol Spectr. 2022. PMID: 36005765 Free PMC article.
-
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.EBioMedicine. 2022 May;79:103986. doi: 10.1016/j.ebiom.2022.103986. Epub 2022 Apr 8. EBioMedicine. 2022. PMID: 35398786 Free PMC article.
-
Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.Vaccine. 2024 Feb 27;42(6):1401-1406. doi: 10.1016/j.vaccine.2024.01.088. Epub 2024 Feb 2. Vaccine. 2024. PMID: 38310015 Review.
-
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022. Front Public Health. 2022. PMID: 35910897 Free PMC article.
Cited by
-
Avidity maturation of anti-spike IgG after vaccination in COVID-19 convalescent vs COVID-19 naïve patients.APMIS. 2025 Jan;133(1):e13489. doi: 10.1111/apm.13489. Epub 2024 Nov 7. APMIS. 2025. PMID: 39509082 Free PMC article.
-
Effects of Prior Infection with SARS-CoV-2 on B Cell Receptor Repertoire Response during Vaccination.Vaccines (Basel). 2022 Sep 6;10(9):1477. doi: 10.3390/vaccines10091477. Vaccines (Basel). 2022. PMID: 36146555 Free PMC article.
-
Use of a Multiplex Immunoassay Platform to Investigate Multifaceted Antibody Responses in SARS-CoV-2 Vaccinees with and Without Prior Infection.COVID. 2025 Apr;5(4):44. doi: 10.3390/covid5040044. Epub 2025 Mar 22. COVID. 2025. PMID: 40406038 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous